January 1, 2012Thrombosis and Haemostasis
Plasma proteomics of patients with non-valvular atrial fibrillation on chronic anti-coagulation with warfarin or a direct factor Xa inhibitor
Why the study?
Does rivaroxaban differentially modulate biologically-relevant plasma proteins compared with warfarin in Japanese subjects with non-valvular chronic atrial fibrillation?
Population
187 Japanese subjects with non-valvular chronic atrial fibrillation
Comparison
Rivaroxaban for 24 weeks vs Warfarin for 24 weeks
Design
RCT, randomly assigned
Follow-up
24 weeks
Authors
Discussion
Loading...
Member takes
Implication
Rivaroxaban differentially affects endothelial biomarkers versus warfarin in AF; extends pharmacoproteomic evidence but does not yet alter clinical practice.
Structured PICO
Does rivaroxaban differentially modulate biologically-relevant plasma proteins compared with warfarin in Japanese subjects with non-valvular chronic atrial fibrillation?
P
Population
187 Japanese subjects with non-valvular chronic atrial fibrillation
I
Intervention
Rivaroxaban for 24 weeks
C
Comparator
Warfarin for 24 weeks
O
Outcome
Differential expression of biologically-relevant plasma proteins over 24 weekssurrogate
Rivaroxaban differentially modulates plasma proteins, notably upregulating thrombomodulin compared to warfarin, suggesting novel pharmacoproteomic effects of factor Xa inhibition beyond standard pharmacodynamic measures.
Cite This Study
Chan et al. (2012) studied this question.